June 19, 2025 - 03:53

Shares of Marvell Technology experienced a remarkable increase of 8.7% during the morning trading session, driven by the company's announcement of a significant advancement in chip technology for Artificial Intelligence (AI). The firm revealed the development of the industry's first 2nm custom Static Random Access Memory (SRAM), a crucial component that enhances the performance of AI chips.
This innovation is poised to revolutionize the efficiency of AI systems by making them faster and more energy-efficient. The introduction of 2nm technology signifies a leap forward in the capabilities of AI chips, allowing companies that rely on massive AI infrastructure to optimize their operations. As industries increasingly adopt AI solutions, the demand for high-performance, low-power chips becomes critical.
Marvell's breakthrough not only positions the company as a leader in the semiconductor space but also underscores the growing importance of advanced memory technologies in the rapidly evolving AI landscape. Investors are responding positively, reflecting confidence in the company's future growth potential.
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...